<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861039</url>
  </required_header>
  <id_info>
    <org_study_id>17078</org_study_id>
    <secondary_id>I8F-JE-GPGP</secondary_id>
    <nct_id>NCT03861039</nct_id>
  </id_info>
  <brief_title>A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes</brief_title>
  <official_title>A Phase 3, Long-Term Safety Study of Tirzepatide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus (SURPASS J-combo)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the long-term safety of the study drug tirzepatide
      in combination with oral antihyperglycemic medications in participants with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 30, 2019</start_date>
  <completion_date type="Anticipated">March 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <description>Number of Participants with One or More SAEs Considered by the Investigator to be Related to Study Drug Administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from Baseline in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve HbA1c &lt;7%</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of Participants who Achieve HbA1c &lt;7%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Serum Glucose</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from Baseline in Fasting Serum Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Average 7-Point Self-Monitored Blood Glucose (SMBG) Values</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from Baseline in average 7-Point SMBG Values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from Baseline in Body Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Weight Loss of ≥5% from Baseline</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of Participants who Achieve Weight Loss of ≥5% from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Insulin</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from Baseline in Fasting Insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting C-Peptide</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from Baseline in Fasting C-Peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Homeostasis Model Assessment B (HOMA-2B)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from Baseline in HOMA-2B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HOMA-2S</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from Baseline in HOMA-2S</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Total Hypoglycemia</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <description>Rate of total hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-Tirzepatide Antibodies</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <description>Number of participants with anti-tirzepatide antibodies</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">441</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>5 mg Tirzepatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg Tirzepatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg tirzepatide administered SC once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg Tirzepatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg tirzepatide administered SC once a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>10 mg Tirzepatide</arm_group_label>
    <arm_group_label>15 mg Tirzepatide</arm_group_label>
    <arm_group_label>5 mg Tirzepatide</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participant must:

          -  Have been diagnosed with type 2 diabetes mellitus based on the World Health
             Organization classification before the screening visit.

          -  Have HbA1c ≥7.0% to &lt;11.0%, as determined by the central laboratory at screening.

          -  Have been taking sulfonylureas, biguanides, thiazolidinedione, alpha-glucosidase
             inhibitor, glinides, or sodium-glucose cotransporter type 2 inhibitor monotherapy for
             at least 3 months before screening and have been on the following dose for at least 8
             weeks before screening.

          -  Have body mass index (BMI) of ≥23 kilograms per meter squared at screening.

          -  Be of stable weight (±5%) during 3 months preceding screening; and agree to not
             initiate an intensive diet and/or exercise program during the study with the intent of
             reducing body weight other than the lifestyle and dietary measures for diabetes
             treatment.

        Exclusion Criteria:

        Participant must not:

          -  Have type 1 diabetes mellitus.

          -  Have had chronic or acute pancreatitis any time prior to study entry.

          -  Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative
             diabetic retinopathy requiring immediate or urgent treatment.

          -  Have disorders associated with slowed emptying of the stomach, or have had any stomach
             surgeries for the purpose of weight loss.

          -  Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or
             blood alanine transaminase (ALT) enzyme level &gt;3.0 times the upper limit of normal
             (ULN) for the reference range, as determined by the central laboratory. Participants
             with nonalcoholic fatty liver disease (NAFLD) are eligible for participation in this
             trial only if there ALT level is ≤3.0 the ULN for the reference range.

          -  Have had a heart attack, stroke, or hospitalization for congestive heart failure in
             the past 2 months.

          -  Have a personal or family history of medullary thyroid carcinoma or personal history
             of multiple endocrine neoplasia syndrome type 2.

          -  Have been taking weight loss drugs, including over-the-counter medications during the
             last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Akaicho Clinic</name>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba</state>
        <zip>260 0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kashiwa hospital</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuri Ono Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manda Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyanomori Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>064-8570</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikeda Hospital</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <zip>661-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakamoto Naika Clinic</name>
      <address>
        <city>Mito</city>
        <state>Ibaraki</state>
        <zip>310 0826</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naka Memorial Clinic</name>
      <address>
        <city>Naka</city>
        <state>Ibaraki</state>
        <zip>311-0113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohishi Naika Clinic</name>
      <address>
        <city>Tsuchiura</city>
        <state>Ibaraki</state>
        <zip>300-0835</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takai Naika Clinic</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <zip>247-0056</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsuruma Kaneshiro Diabetes Clinic</name>
      <address>
        <city>Yamato</city>
        <state>Kanagawa</state>
        <zip>242-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Minoru Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.E.C. Science Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>235-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takatsuki Red Cross Hospital</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-1096</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsu City Hospital</name>
      <address>
        <city>Otsu</city>
        <state>Shiga</state>
        <zip>520-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakakusa Clinic</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329-0433</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seiwa Clinic</name>
      <address>
        <city>Adachi-ku</city>
        <state>Tokyo</state>
        <zip>123 0845</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HDC Atlas Clinic</name>
      <address>
        <city>Chiyoda</city>
        <state>Tokyo</state>
        <zip>102-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asahi Life Foundation Adult Disease Research Center</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103 0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihonbashi Sakura Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo-Eki Center-building Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Center Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Trial Centre Fukuwa Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanno Naika</name>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <zip>181 0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinjuku Research Park Clinic</name>
      <address>
        <city>Shinjuku-Ku</city>
        <state>Tokyo</state>
        <zip>169-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Futata Tetsuhiro Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>819 0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morinaga Ueno Clinic</name>
      <address>
        <city>Kumamoto</city>
        <zip>860 0863</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinnouchi Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>862-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abe Diabetes Clinic</name>
      <address>
        <city>Oita</city>
        <zip>870-0039</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Noe Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>536 0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitada Clinic</name>
      <address>
        <city>Osaka</city>
        <zip>538 0044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Denryoku Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>553-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka City Shizuoka Hospital</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-8630</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suruga Clinic</name>
      <address>
        <city>Shizuoka</city>
        <zip>424-0855</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/2qJ9f49B7nrO6hGapNnDZD?conditionId=3bqjr5JHpKymwsYAWWaicU</url>
    <description>A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes</description>
  </link>
  <verification_date>June 15, 2020</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>LY3298176</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

